⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 5, 2026Australasian Journal of Dermatology

Real‐World Persistence of Upadacitinib for Atopic Dermatitis: Expanded Analysis From Royal Melbourne Hospital Biogrid Registry and the Australasian Dermatology Registry

Nadine Abu‐Ghazaleh Julie Armstrong Vanessa Morgan Gayle Ross

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to analyze the real-world persistence of upadacitinib therapy in patients with atopic dermatitis.
Data were sourced from the Royal Melbourne Hospital Biogrid Registry and the Australasian Dermatology Registry.
Analysis focused on treatment duration and adherence to upadacitinib therapy.
The findings suggest significant persistence rates of upadacitinib in real-world settings.
Patients showed improved symptoms of atopic dermatitis with sustained therapy.
Long-term data support the effectiveness and usability of upadacitinib.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Expanded analysis reveals the effectiveness of upadacitinib for atopic dermatitis in diverse populations, emphasizing its usability.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Abu‐Ghazaleh et al. (2026) studied this question.

synapsesocial.com/papers/6a76daf2f12abadc79815c0c https://doi.org/10.1111/ajd.70188

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-World Effectiveness, Safety, and 36-Month Persistence of Upadacitinib in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: The 3–6 Month Critical Window and the Role of Early Itch Response and Psychotropic Medication UseCohort Study · 2026
2Cumulative Disease Control with Upadacitinib in Moderate-to-Severe Atopic Dermatitis—A 52-Week Multicenter Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)Retrospective Study · 2026
3Time‐Varying Acne Risk After Upadacitinib Initiation in Atopic Dermatitis: A New‐User, Active‐Comparator Retrospective StudyCohort Study · 2026
4Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study2024 · 10 citations
5Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study2024 · 27 citations

Persistence of Biologics and JAK Inhibitors in Atopic Dermatitis: Preliminary 24-Month Analysis2026
Real-World Efficacy and Safety of Upadacitinib in Korean Patients With Atopic Dermatitis2026
645 - Effectiveness and safety of upadacitinib in adolescent and adult patients with atopic dermatitis: an analysis of long-term (week 52) data from a real-world multicenter retrospective review2024
Prevalence of Hyperhidrosis: An Australian Population StudyAustralasian Journal of Dermatology · 2026
Real‐World Outcomes of Rituximab in Pemphigus: An Australian Tertiary CohortAustralasian Journal of Dermatology · 2026

More from Australasian Journal of Dermatology

More from The University of Melbourne

More from The Royal Melbourne Hospital

More from Skin Health Institute